Soligenix Inc.

Name: Soligenix Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

Headquarters: Princeton, NJ, United States of America

Website: http://www.soligenix.com

Year Founded: 1987

Status: Public

Industry Sector: HealthTechnology

CEO: Christopher J. Schaber, PhD

Number Of Employees: 15

Enterprise Value: $922,788

PE Ratio: -0.29

Exchange/Ticker 1: NASDAQ:SNGX

Exchange/Ticker 2: N/A

Latest Market Cap: $5,771,800

BioCentury | Feb 14, 2023

Deals

Feb. 14 Quick Takes: Vir to advance next-gen COVID assets without GSK

Plus: Cullinan licenses HBM bispecific and updates from Fusion, BioXcel, Incyte and more

BioCentury | Dec 15, 2021

Management Tracks

Acadia promotes Schneyer to CFO

Plus: Iveric bio, Mind Medicine, Norwest, Affinia and more

BioCentury | Oct 1, 2021

Translation in Brief

Mapping protein interaction networks to uncover new cancer targets

Plus: OncoCyte, MISER, GSK and more

BioCentury | Dec 2, 2020

Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

DISEASE CATEGORY: Infectious disease
INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial

BioCentury | Nov 25, 2020

Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and

BioCentury | Apr 17, 2020

Product Development